Why Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?
Why Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?
Monday, Viracta Therapeutics Inc (NASDAQ:VIRX) reported topline results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial from both arms of the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort.
周一，Viracta Therapeutics Inc（纳斯达克股票代码：VIRX）报告了来自复发或难治性（R/R）爱泼斯坦-巴尔病毒阳性（EBV+）外周T细胞淋巴瘤（PTCL）队列两个组的关键2期 NAVAL-1 试验的第一阶段的主要结果。
Patients were randomized to either nanatinostat monotherapy (n=10) or nanatinostat in combination with valganciclovir (Nana-val, n=10).
患者被随机分配使用纳那替诺司他单一疗法（n=10）或纳那替诺司他与缬更昔洛韦联合使用（Nana-VAL，n=10）。
Nana-val (nanatinostat in combination with valganciclovir) demonstrated greater efficacy than nanatinostat monotherapy and was generally well-tolerated. The median duration of response continues to mature.
Nana-VAL（纳那替诺司他与缬更昔洛韦联合使用）显示出比纳那替诺司他单一疗法更高的疗效，并且总体耐受性良好。中位反应持续时间继续成熟。
Efficacy was evaluated as of the February 7, 2024 data cutoff date.
截至2024年2月7日数据截止日期，对疗效进行了评估。
- In the Nana-val arm, the overall response rate (ORR) was 50%, and the complete response rate (CRR) was 20% in the intent-to-treat (ITT) population (N=10); the ORR was 71%, and the CRR was 29% in the efficacy-evaluable population (N=7).
- 在Nana-val组中，总缓解率（ORR）为50％，意向治疗（ITT）人群的完全反应率（CRR）为20％（N=10）；ORR为71％，疗效可评估人群的CRR为29％（N=7）。
In the nanatinostat monotherapy arm, the ORR and CRR were 10% and 0%, respectively, in the ITT population (N=10), and the ORR was 13% in the efficacy-evaluable population (N=8).
在nanatinostat单一疗法组中，ITT人群中的ORR和CRR分别为10％和0％（N=10），疗效可评估人群中的ORR为13％（N=8）。
- Five nanatinostat monotherapy patients crossed over to receive Nana-val, two of whom remain on Nana-val treatment with stable disease as of the data cutoff.
- 五名nanatinostat单一疗法患者跨境接受了Nana-Val治疗，截至数据截止，其中两人仍在接受Nana-Val治疗，病情稳定。
Safety was also evaluated as of the February 7, 2024 data cutoff date.
截至2024年2月7日数据截止日期，还对安全性进行了评估。
The most common treatment-related adverse events in both treatment arms were thrombocytopenia, anemia, fatigue, decreased appetite, nausea, diarrhea, and weight loss.
两个治疗组中最常见的治疗相关不良事件是血小板减少症、贫血、疲劳、食欲不振、恶心、腹泻和体重减轻。
These adverse events were primarily mild to moderate in severity and generally manageable or reversible.
这些不良事件的严重程度主要为轻度至中度，通常是可控制或可逆的。
Price Action: VIRX shares are down 15.7% at $0.97 on the last check Monday.
价格走势：周一的最后一次支票中，VIRX股价下跌15.7％，至0.97美元。
Illustration of Phrama lab worker created with MidJourney.
使用 MidJourney 创作的 Phrama 实验室工作人员的插图。